HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

VIR-7832

SARS-CoV-2 neutralizing antibody

Also Known As:

GSK 4182137; GSK-4182137; GSK4182137; VIR 7832; VIR7832

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        VIR-7832: 1
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        VIR-7832: 1
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        VIR-7832: 1

Experts

1.	Ho, Mitchell: 1 article (12/2020)
2.	Sun, Yaping: 1 article (12/2020)

Related Diseases

1.

12/01/2020 - "As of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike protein have entered clinical trials with three (REGN-COV2, LY3819253/LY-CoV555, and VIR-7831/VIR-7832) in phase 3. On 9 November 2020, the US Food and Drug Administration issued an emergency use authorization for bamlanivimab (LY3819253/LY-CoV555) for the treatment of mild-to-moderate COVID-19. "

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	bamlanivimab
3.	SARS-CoV-2 spike protein